134 related articles for article (PubMed ID: 26514470)
1. Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy.
Alkhatib A; Gomaa A; Allam N; Rewisha E; Waked I
Asian Pac J Cancer Prev; 2015; 16(16):6929-34. PubMed ID: 26514470
[TBL] [Abstract][Full Text] [Related]
2. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
3. Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
Peng Z; Chen S; Wei M; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Chen M; Qian G; Kuang M
Radiology; 2018 May; 287(2):705-714. PubMed ID: 29390197
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
[TBL] [Abstract][Full Text] [Related]
5. Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C.
Wang JH; Kuo YH; Wang CC; Chen CL; Cheng YF; Hsu HC; Lu SN
Dig Liver Dis; 2013 Jun; 45(6):510-5. PubMed ID: 23218990
[TBL] [Abstract][Full Text] [Related]
6. Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model.
Chan YC; Kabiling CS; Pillai VG; Aguilar G; Wang CC; Chen CL
World J Surg; 2015 Jun; 39(6):1510-8. PubMed ID: 25665673
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hepatocellular carcinoma: beyond international guidelines.
Sangiovanni A; Colombo M
Liver Int; 2016 Jan; 36 Suppl 1():124-9. PubMed ID: 26725909
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System.
Kikuchi L; Oliveira CP; Alvares-da-Silva MR; Tani CM; Diniz MA; Stefano JT; Chagas AL; Alencar RS; Vezozzo DC; Santos GR; Campos PB; Alves VA; Ratziu V; Carrilho FJ
Am J Clin Oncol; 2016 Oct; 39(5):428-32. PubMed ID: 25268068
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
12. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
[TBL] [Abstract][Full Text] [Related]
13. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes.
Ramanathan R; Sharma A; Lee DD; Behnke M; Bornstein K; Stravitz RT; Sydnor M; Fulcher A; Cotterell A; Posner MP; Fisher RA
Transplantation; 2014 Jul; 98(1):100-6. PubMed ID: 24503764
[TBL] [Abstract][Full Text] [Related]
14. Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group.
Leoni S; Piscaglia F; Serio I; Terzi E; Pettinari I; Croci L; Marinelli S; Benevento F; Golfieri R; Bolondi L
Dig Liver Dis; 2014 Jun; 46(6):549-55. PubMed ID: 24630947
[TBL] [Abstract][Full Text] [Related]
15. Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study.
Sato Y; Nishiofuku H; Yasumoto T; Nakatsuka A; Matsuo K; Kodama Y; Okubo H; Abo D; Takaki H; Inaba Y; Yamakado K
J Vasc Interv Radiol; 2018 Aug; 29(8):1061-1067. PubMed ID: 29934260
[TBL] [Abstract][Full Text] [Related]
16. Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era.
Waziry R; Gomaa A; Waked I; Dore GJ
Arab J Gastroenterol; 2018 Mar; 19(1):26-32. PubMed ID: 29506913
[TBL] [Abstract][Full Text] [Related]
17. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
Chao Y; Chung YH; Han G; Yoon JH; Yang J; Wang J; Shao GL; Kim BI; Lee TY
Int J Cancer; 2015 Mar; 136(6):1458-67. PubMed ID: 25099027
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Geschwind JF; Chapiro J
Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101
[No Abstract] [Full Text] [Related]
19. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
20. Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C).
Schmidt L; op den Winkel M; Fischer K; Straub G; Rauch B; Paprottka PM; Göke B; Kolligs FT
Digestion; 2014; 90(4):219-28. PubMed ID: 25502689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]